150 related articles for article (PubMed ID: 17221181)
21. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia.
Earnshaw SR; Candrilli SD; Fernandes AW; Higashi MK
Manag Care Interface; 2005 Oct; 18(10):36-44. PubMed ID: 16265933
[TBL] [Abstract][Full Text] [Related]
22. [Clinical efficacy of probiotics in complex treatment of called-up servicemen with community-acquired pneumonia].
Rakov AL; Grinevich VB; Kriukov AE; Bogdanov IV; Rysev AV; Zakharchenko MM; Dobrenko VA; Gubonina IV
Voen Med Zh; 2006 Apr; 327(4):15-22. PubMed ID: 16784101
[No Abstract] [Full Text] [Related]
23. Transitional (intravenous to oral) antibiotic therapy.
Quintiliani R; Grant E; Quintiliani R
J Med Liban; 2000; 48(4):233-40. PubMed ID: 11214195
[TBL] [Abstract][Full Text] [Related]
24. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
25. Hospital-based strategies to reduce antibiotic resistance: are they valid in the community setting?
Tillotson GS; Blondeau JM; Carroll J
Expert Rev Anti Infect Ther; 2007 Feb; 5(1):53-9. PubMed ID: 17266453
[TBL] [Abstract][Full Text] [Related]
26. Community-acquired pneumonia. Cost-effective antimicrobial therapy.
Cunha BA
Postgrad Med; 1996 Jan; 99(1):109-10, 113-4, 117-9, passim. PubMed ID: 8539197
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis.
Li JZ; Winston LG; Moore DH; Bent S
Am J Med; 2007 Sep; 120(9):783-90. PubMed ID: 17765048
[TBL] [Abstract][Full Text] [Related]
28. Modified guidelines impact on antibiotic use and costs: duration of treatment for pneumonia in a neurosurgical ICU is reduced.
Meyer E; Buttler J; Schneider C; Strehl E; Schroeren-Boersch B; Gastmeier P; Ruden H; Zentner J; Daschner FD; Schwab F
J Antimicrob Chemother; 2007 Jun; 59(6):1148-54. PubMed ID: 17434880
[TBL] [Abstract][Full Text] [Related]
29. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
[TBL] [Abstract][Full Text] [Related]
30. How long should we treat community-acquired pneumonia?
Scalera NM; File TM
Curr Opin Infect Dis; 2007 Apr; 20(2):177-81. PubMed ID: 17496577
[TBL] [Abstract][Full Text] [Related]
31. Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.
Tillotson GS; Echols RM
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S237-40. PubMed ID: 18986296
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacoeconomic estimation of cost of community acquired pneumonia therapy].
Kulidzhanov AIu; Sirotko II; Koriakin PM; Korchazhkin VS
Voen Med Zh; 2001 Jan; 322(1):50-2. PubMed ID: 11219929
[No Abstract] [Full Text] [Related]
33. Role of gemifloxacin in community-acquired pneumonia.
Tillotson GS
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
[TBL] [Abstract][Full Text] [Related]
34. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Rapp RP
Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
[TBL] [Abstract][Full Text] [Related]
35. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli.
Falguera M; Carratalà J; Ruiz-Gonzalez A; Garcia-Vidal C; Gazquez I; Dorca J; Gudiol F; Porcel JM
Respirology; 2009 Jan; 14(1):105-11. PubMed ID: 18699803
[TBL] [Abstract][Full Text] [Related]
36. Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain.
Tellado JM; Sen SS; Caloto MT; Kumar RN; Nocea G
Scand J Infect Dis; 2007; 39(11-12):947-55. PubMed ID: 17852889
[TBL] [Abstract][Full Text] [Related]
37. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock.
Rodríguez A; Mendia A; Sirvent JM; Barcenilla F; de la Torre-Prados MV; Solé-Violán J; Rello J;
Crit Care Med; 2007 Jun; 35(6):1493-8. PubMed ID: 17452932
[TBL] [Abstract][Full Text] [Related]
38. Balancing the benefits and costs of antibiotic drugs: the TREAT model.
Leibovici L; Paul M; Andreassen S
Clin Microbiol Infect; 2010 Dec; 16(12):1736-9. PubMed ID: 20673259
[TBL] [Abstract][Full Text] [Related]
39. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
40. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial.
Schouten JA; Hulscher ME; Trap-Liefers J; Akkermans RP; Kullberg BJ; Grol RP; van der Meer JW
Clin Infect Dis; 2007 Apr; 44(7):931-41. PubMed ID: 17342644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
